.Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BC09_Rotigotine.Rotigotine .Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BC09_Rotigotine.Rotigotine| name: | Rotigotine |
| ATC code: | N04BC09 | route: | transdermal |
| n-compartments | 1 |
Rotigotine is a non-ergoline dopamine agonist used in the treatment of Parkinson's disease and restless legs syndrome. It is administered via a transdermal patch and is approved for clinical use in many countries.
Pharmacokinetic parameters reported for healthy adult subjects and patients with Parkinson's disease following repeated transdermal administration.
Cawello, W, et al., & Funaki, T (2016). Pharmacokinetics, safety, and tolerability of rotigotine transdermal system in healthy Japanese and Caucasian subjects following multiple-dose administration. European journal of drug metabolism and pharmacokinetics 41(4) 353–362. DOI:10.1007/s13318-015-0273-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25773763
Cawello, W, et al., & Funaki, T (2014). Pharmacokinetics, safety and tolerability of rotigotine transdermal patch in healthy Japanese and Caucasian subjects. Clinical drug investigation 34(2) 95–105. DOI:10.1007/s40261-013-0150-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24178238
Liu, Y, et al., & Elshoff, JP (2018). Pharmacokinetics, Tolerability, and Bioequivalence of Two Formulations of Rotigotine in Healthy Chinese Subjects. Clinical therapeutics 40(7) 1108–1121.e8. DOI:10.1016/j.clinthera.2018.05.009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30098648